TABLE 1.
Baseline characteristics
| Characteristics | Overall patients (n = 128) |
|---|---|
| Age (y) | |
| Median (range) | 51(23–77) |
| <65 | 116 (90.6) |
| ≥65 | 12 (9.4) |
| Sex, n (%) | |
| Male | 61 (47.7) |
| Female | 67 (52.3) |
| Smoking history, n (%) | |
| Yes | 33 (25.8) |
| No | 95 (74.2) |
| ECOGPS, n (%) | |
| 0 | 4 (3.2) |
| 1 | 122 (95.2) |
| 2 | 2 (1.6) |
| Pathological type, n (%) | |
| Adenocarcinoma | 120 (93.7) |
| Non‐adenocarcinoma | 8 (6.3) |
| Stage at diagnosis, n (%) | |
| III B | 14 (10.9) |
| IV | 114 (89.1) |
| Site of distant metastases, n (%) | |
| Bone | 50 (39.1) |
| Brain | 46 (35.9) |
| Liver | 23 (18.0) |
| Adrenal gland | 9 (7.0) |
| Number of distant metastases, n (%) | |
| <4 | 108 (84.4) |
| ≥4 | 20 (15.6) |
| Testing method | |
| FISH | 62 (48.5) |
| IHC | 22 (17.2) |
| RT‐PCR | 16 (12.5) |
| NGS | 3 (2.3) |
| Unknown | 25 (19.5) |
| ALK‐TKI as first‐line therapy, n (%) | |
| Yes | 49 (38.3) |
| No | 79 (61.7) |
| Number of ALK‐TKI, n (%) | |
| 1 | 65 (50.8) |
| 2 | 44 (34.4) |
| ≥3 | 19 (14.8) |
Abbreviations: y, years; ECOG‐PS, Eastern Cooperative Oncology Group‐performance status; FISH, fluorescence in situ hybridization; IHC, immunohistochemistry; RT‐PCR, real time‐polymerase chain reaction; NGS, next generation sequencing; ALK‐ TKI, anaplastic lymphoma kinase‐tyrosine kinase inhibitor.